Tag:
laquinimod
Latest Headlines
Latest Headlines
Teva touts fresh PhIII evidence of oral MS drug's potential
Teva and its multiple sclerosis partner Active Biotech rolled out some new top-line Phase III data on their troubled program for the oral multiple sclerosis drug laquinimod--still Teva's best shot at protecting the $4 billion franchise built up for Copaxone.
Teva looks set for a new round of M&A deals
Don't be too surprised if Teva starts to make fresh headlines on the M&A side of the business. CEO Shlomo Yanai is telling reporters the company is acutely aware of just how badly it needs to
Teva's oral MS drug trips (again) in blockbuster Ph3 development race
Teva's late-stage oral MS drug laquinimod flunked the second of three Phase III studies, the latest in a series of disappointments. Company officials say they can explain why the treatment failed to
Teva's oral MS drug data disappoints the analysts
With a multibillion-dollar market at stake, Teva shares were dented yesterday afternoon after word spread that its oral MS drug laquinimod cut relapses at a lower rate than standard injectable
Teva's laquinimod for MS gets fast tracked
Israel-based Teva Pharmaceutical announced today that the FDA has granted the Fast Track designation to laquinimod, its investigational treatment for relapsing-remitting multiple sclerosis (RRMS).
